Phase II Study of Mocetinostat (MGCD0103) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma

BACKGROUND: The prognosis of patients with relapsed Hodgkin lymphoma, especially those who relapsed after stem cell transplant, remains poor, and the development of new agents for this relatively young patient population represents an unmet medical need. In this study, we examined the safety and eff...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet Oncol
Auteurs principaux: Younes, Anas, Oki, Yasuhiro, Bociek, R. Gregory, Kuruvilla, John, Fanale, Michelle, Neelapu, Sattva, Copeland, Amanda, Buglio, Daniela, Galal, Ahmed, Besterman, Jeffrey, Li, Zuomei, Drouin, Michel, Patterson, Tracy, Ward, M. Renee, Paulus, Jessica K., Ji, Yuan, Medeiros, L. Jeffrey, Martell, Robert E.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5042214/
https://ncbi.nlm.nih.gov/pubmed/22033282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70265-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires